newsfilter
← Latest News
GlobeNewswire·

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep"